Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | MGAM | O43451 | 1/20 | 0.54 |
| ▸ | SI | P14410 | 1/20 | 0.54 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TOP2A | P11388 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10757823 | 0.98 | GAA (0.52) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL13151291 | 0.91 | MGAM (0.40) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL4464939 | 0.91 | GAA (0.59) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL13756031 | 0.88 | GAA (0.56) | GAAMGAMSIMGAM2CYP1A2 | |
| Hydrochloric Acid SCHEMBL11851530 | 0.88 | GAA (0.56) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL8367259 | 0.87 | CYP1A2 (0.55) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL837763 | 0.84 | ALDH1A1 (0.57) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL20937509 | 0.84 | LTA4H (0.52) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL12939654 | 0.84 | GAA (0.52) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL19102485 | 0.84 | GAA (0.52) | GAAMGAMSIMGAM2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0449989-A1 | 6,7 DIHYDROPYRROLO 3,4-c] PYRIDO 2,3-d] PYRIMIDINE DERIVATIVES | Sloan-Kettering Institute For Cancer Research (US) | 1991-10-09 | — | — | EP | claimed |
| WO-1990007496-A1 | 6,7 DIHYDROPYRROLO[3,4-c] PYRIDO[2,3-d] PYRIMIDINE DERIVATIVES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1990-07-12 | — | — | WO | claimed |
| US-12371432-B2 | Haloallylamine compounds and application thereof | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2025-07-29 | — | — | US | disclosed |
| US-12227501-B2 | 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as CSNK1 inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2025-02-18 | — | — | US | disclosed |
| EP-3892621-B1 | HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF | TRANSTHERA SCIENCES NANJING INC (CN) | 2024-09-18 | — | — | EP | disclosed |
| US-12077510-B2 | Carboxylic acid compounds | Sumitomo Pharma Co., Ltd. (JP) | 2024-09-03 | — | — | US | disclosed |
| US-11753371-B2 | Disulfiram derivatives as ALDH1A1 and MAGL inhibitors | BATTERJEE MEDICAL COLLEGE (SA) | 2023-09-12 | — | — | US | disclosed |
| US-11753371-B2 | Disulfiram derivatives as ALDH1A1 and MAGL inhibitors | BATTERJEE MEDICAL COLLEGE (SA) | 2023-09-12 | — | — | US | disclosed |
| EP-3921317-B1 | 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS | BAYER AG (DE) | 2023-08-02 | — | — | EP | disclosed |
| EP-3921317-B1 | 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS | BAYER AG (DE) | 2023-08-02 | — | — | EP | disclosed |
| US-20230174474-A1 | DISULFIRAM DERIVATIVES AS ALDH1A1 AND MAGL INHIBITORS | BATTERJEE MEDICAL COLLEGE (SA) | 2023-06-08 | — | — | US | disclosed |
| EP-0031120-B1 | A PROCESS FOR THE PRODUCTION OF 2-SUBSTITUTED 6-ALKOXYCARBONYL-8-ETHYL-5-OXO-5,8-DIHYDRO-PYRIDO(2,3-D)-PYRIMIDINES AND OF CORRESPONDING FREE ACIDS | Unibios S.p.A. (IT) | 1984-08-01 | — | — | EP | disclosed |
| EP-0018549-B1 | TETRAHYDROISOQUINOLINE COMPOUNDS, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Tanabe Seiyaku Co., Ltd. (JP) | 1981-12-30 | — | — | EP | disclosed |
| US-4294832-A | HYPOTENSIVE AGENTS, ANGIOTENSIN INHIBITORS | TANABE SEIYAKU CO., LTD. (JP) | 1981-10-13 | — | — | US | disclosed |
| EP-0031120-A1 | A process for the production of 2-substituted 6-alkoxycarbonyl-8-ethyl-5-oxo-5,8-dihydro-pyrido(2,3-d)-pyrimidines and of corresponding free acids | Unibios S.p.A. (IT) | 1981-07-01 | — | — | EP | disclosed |
| EP-0018549-A2 | Tetrahydroisoquinoline compounds, process for preparing them and pharmaceutical compositions containing them | Tanabe Seiyaku Co., Ltd. (JP) | 1980-11-12 | — | — | EP | disclosed |
| US-4129737-A | Process for the preparation of an 8-alkyl-5-oxo-5,8-dihydro-pyrido(2,3-d)pyrimidine-6-carboxylic acid | LABORATOIRE ROGER BELLON (FR) | 1978-12-12 | — | — | US | disclosed |
| US-4125720-A | Process for the preparation of 4-chloro-5-alkoxycarbonyl-2-methoxy-pyrimidines | LABORATOIRE ROGER BELLON (FR) | 1978-11-14 | — | — | US | disclosed |
| US-4034094-A | 8-Alkyl-5-oxo-5,8-dihydro-pyrido(2,3-d)pyrimidine-6-carboxylic acids for treating urinary tract infections | LABORATOIRE ROGER BELLOW (FR) | 1977-07-05 | — | — | US | disclosed |
| US-3950338-A | BACTERICIDES | LABORATOIRE ROGER BELLON (FR) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371432-B2 | Haloallylamine compounds and application thereof | ADRA1D, ADRA1A, VAPA | GAA 2675/4885MGAM 3943/4885SI 4741/4885 |
| US-12077510-B2 | Carboxylic acid compounds | C9, C3AR1, SUCNR1 | GAA 225/4885MGAM 1508/4885SI 1255/4885 |
| US-11753371-B2 | Disulfiram derivatives as ALDH1A1 and MAGL inhibitors | ALDH1A1, ADH1A, ALDH3A1 | GAA 307/4885MGAM 281/4885SI 2681/4885 |
| US-12227501-B2 | 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as CSNK1 inhibitors | CSNK1A1, CSNK1G1, CSNK1E | GAA 1002/4885MGAM 4396/4885SI 2717/4885 |
| US-20230174474-A1 | DISULFIRAM DERIVATIVES AS ALDH1A1 AND MAGL INHIBITORS | ALDH1A1, ADH1A, ALDH3A1 | GAA 307/4885MGAM 281/4885SI 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.